natgillin/translations-raw huggingface dataset:
Meget sjælden Leukopeni, trombocytopeni, allergiske reaktioner, hyperglykæmi, hypertoni, perifer neuropati, myokardieinfarkt, arytmi (herunder bradykardi, ventrikulær takykardi og atrieflimren), vaskulitis, pankreatitis, gastritis, gingival hyperplasi, hepatitis, gulsot, forhøjede leverenzymer*, angioødem, erythema multiforme, urticaria, eksfoliativ dermatitis, Stevens-Johnsons syndrom, quinckes ødem, lysfølsomhed.
Very rare Leukocytopenia, thrombocytopenia, allergic reactions, hyperglycaemia, hypertonia, peripheral neuropathy, myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation), vasculitis, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, hepatic enzymes increased*, angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity.
Den maksimale anbefalede dosis til patienter med letlet til moderat nedsat leverfunktion uden kolestase er 80 mg valsartan.
In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan.
Valsartan udskilles hovedsageligt via galden.
Valsartan is mostly eliminated unchanged via the bile.
- hvis du er mere end 3 måneder henne i graviditeten (brug af Dafiro tidligt i graviditeten bør også undgås, se afsnittet om Graviditet).
(It is also better to avoid Dafiro in early pregnancy, see Pregnancy section).
Øvrige indholdsstoffer: mikrokrystallinsk cellulose; crospovidon (type A); kolloid vandfri silica; magnesiumstearat; hypromellose (substitutionstype 2910 (3 mPa.s)); macrogol 4000; talcum; titandioxid (E171); gul jernoxid (E172).
The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous; magnesium stearate; hypromellose (substitution type 2910 (3 mPa.s)); macrogol 4000; talc, titanium dioxide (E171); iron oxide, yellow (E172).
Ikke kendt (hyppigheden kan ikke klarlægges ud fra de tilgængelige data): Nedsat antal røde blodlegemer i blodet, feber, ondt i halsen eller sår i munden pga. infektioner; pludselige blødninger eller blå mærker; forhøjet kaliumniveau i blodet; unormale testresultater for leveren; nedsat nyrefunktion og alvorlig nedsat nyrefunktion; hævelse hovedsageligt i ansigt og hals; muskelsmerter; uslæt, lilla-farvede mærker; feber; kløe; overfølsomhedsreaktioner; blærer på huden (tegn på en lidelse kaldet bulløs dermatit).
Not known (frequency cannot be estimated from the available data): Decrease in red blood cells, fever, sore throat or mouth sores due to infections; spontaneous bleeding or bruising; high level of potassium in the blood; abnormal liver test results; decreased renal functions and severely decreased renal functions; swelling mainly of the face and the throat; muscle pain; rash, purplish-red spots; fever; itching; allergic reaction; blistering skin (sign of a condition called dermatitis bullous).
Ekstrapyramidalt syndrom -
Extrapyramidal syndrome
I et klinisk studie med patienter, som tidligere havde haft tør hoste under behandling med en ACE-hæmmer, oplevede 19,5% af patienterne, som fik valsartan, og 19,0% af dem, som fik thiazid-diuretika, hoste.
In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide diuretic experienced coughing, compared to 68.5% of those treated with an ACE inhibitor (p <0.05).
Almindelige (kan forekomme hos op til 1 ud af 10 personer): Influenza; stoppet næse; ondt i halsen og ubehag, når der skal synkes; hovedpine; hævede arme, hænder, ben, ankler eller fødder; træthed; asteni (svaghed); rødme og varmefornemmelse i ansigt og/eller hals.
Common (may affect up to 1 in 10 people): Influenza (flu); blocked nose, sore throat and discomfort when swallowing; headache; swelling of arms, hands, legs, ankles or feet; tiredness; asthenia (weakness); redness and warm feeling of the face and/or neck.
Dafiro 10 mg/160 mg kan gives til patienter, hvis blodtryk ikke er tilstrækkeligt kontrolleret med amlodipin 10 mg eller valsartan 160 mg alene eller med Dafiro 5 mg/160 mg.
Dafiro 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Dafiro 5 mg/160 mg.
Patienter med natrium- og/eller væskemangel
Sodium- and/or volume-depleted patients
Quinckes ødem
Quincke oedema
Sjældne (kan forekomme hos op til 1 ud af 1.000 personer): Angstfølelse; ringen for ørene (tinnitus); besvimelse; større urinproduktion end normalt eller forøget trang til vandladning; manglende evne til at få eller vedholde erektion; følelsen af tunghed; for lavt blodtryk med symptomer som svimmelhed, uklarhed; øget svedtendens; hududslæt over hele kroppen, kløe, muskelkramper.
Rare (may affect up to 1 in 1,000 people): Feeling anxious; ringing in the ears (tinnitus); fainting; passing more urine than normal or feeling more of an urge to pass urine; inability to get or maintain an erection; sensation of heaviness; low blood pressure with symptoms such as dizziness, lightheadedness; excessive sweating; skin rash all over your body; itching; muscle spasm.
Øvrige indholdsstoffer: mikrokrystallinsk cellulose; crospovidon (type A); kolloid vandfri silica; magnesiumstearat; hypromellose (substitutionstype 2910 (3 mPa.s)); macrogol 4000; talcum; titandioxid (E171); gul jernoxid (E172); rød jernoxid (E172).
The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous; magnesium stearate; hypromellose (substitution type 2910 (3 mPa.s)); macrogol 4000; talc, titanium dioxide (E171); iron oxide, yellow (E172), iron oxide, red (E172).
Ikke almindelig Insomni, humørsvingninger (inklusive angst), depression, tremor, smagsforstyrrelser, synkope, hypæstesi, synsforstyrrelser (herunder diplopi), tinnitus, hypotension, dyspnø, rhinitis, opkastning, dyspepsi, alopeci, purpura, misfarvning af huden, hyperhidrose, pruritus, eksantem, myalgi, muskelkramper, smerter, vandladningsforstyrrelser, øget vandladningshyppighed, impotens, gynækomasti, brystsmerter, utilpashed, vægtstigning, vægttab.
Uncommon Insomnia, mood changes (including anxiety), depression, tremor, dysgeusia, syncope, hypoesthesia, visual disturbance (including diplopia), tinnitus, hypotension, dyspnoea, rhinitis, vomiting, dyspepsia, alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, exanthema, myalgia, muscle cramps, pain, micturition disorder, increased urinary frequency, impotence, gynaecomastia, chest pain, malaise, weight increase, weight decrease.
Hvis noget af følgende sker for dig, skal du straks kontakte din læge: Overfølsomhedsreaktioner med symptomer som udslæt, kløe, hævet ansigt, læber eller tunge, svært ved at få luft, for lavt blodtryk (følelsen af bevidstløshed, uklarhed).
Allergic reaction with symptoms such as rash, itching, swelling of face or lips or tongue, difficulty breathing, low blood pressure (feeling of faintness, light-headedness).
CYP3A4-inducerende stoffer (antikrampemidler [f.eks. carbamazepin, phenobarbital, phenytoin, fosphenytoin, primidon], rifampicin, perikon)
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum) Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine may vary.
intens kløe, blæredannelse, afskalning eller hævelse i huden, betændelseslignende tilstand i slimhinderne (Stevens-Johnsons syndrom, toksisk epidermal nekrolyse) eller andre allergiske reaktioner.
- Severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of the mucous membranes (Stevens-Johnson Syndrome, toxic epidermal necrolysis) or other allergic reactions.
Dobbelthæmning af RAAS ved kombination af ACE-hæmmere med ARBer eller aliskiren frarådes derfor (se pkt.
Dual blockade of RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is therefore not recommended (see sections 4.5 and 5.1).
Dafiro 5 mg/80 mg kan gives til patienter, hvis blodtryk ikke er tilstrækkeligt kontrolleret med amlodipin 5 mg eller valsartan 80 mg alene.
Dafiro 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone.
Histopatologiske tegn på inflammation i maveslimhinden blev set hos hanrotter ved en eksponering ca. 1,9 (valsartan) og 2,6 (amlodipin) gange de kliniske doser på 160 mg valsartan og 10 mg amlodipin.
Adverse reactions observed in animal studies with possible clinical relevance were as follows: Histopathological signs of inflammation of the glandular stomach was seen in male rats at an exposure of about 1.9 (valsartan) and 2.6 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine.
4.1) med nedsat leverfunktion skiftes til amlodipin eller Dafiro, skal den laveste tilgængelige dosis af henholdvis amlodipin-monoterapi eller amlodipinkombination anvendes.
When switching eligible elderly hypertensive patients (see section 4.1) to amlodipine or Dafiro, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.
Symptomatisk hypotension kan forekomme hos patienter med et aktiveret renin-angiotensin-system (f.eks. patienter med væskeog/eller natrium mangel, der får høje doser af diuretika), som behandles med angiotensinreceptorblokkere.
In patients with an activated renin-angiotensin system (such as volume- and/or salt-depleted patients receiving high doses of diuretics) who are receiving angiotensin receptor blockers, symptomatic hypotension may occur.
Dafiro 10 mg/160 mg tabletter er ovale og lysegule, præget med ”NVR” på den ene side og ”UIC” på den anden side.
Dafiro 10 mg/160 mg tablets are oval and light yellow with “NVR” on one side and “UIC” on the other side.
Misfarvning af huden
Skin discolouration
Dafiro 5 mg/160 mg tabletter er ovale og mørkegule, præget med ”NVR” på den ene side og ”ECE” på den anden side.
Dafiro 5 mg/160 mg tablets are oval and dark yellow “NVR” on one side and “ECE” on the other side.
Dafiro 5 mg/160 mg kan gives til patienter, hvis blodtryk ikke er tilstrækkeligt kontrolleret med amlodipin 5 mg eller valsartan 160 mg alene.
Dafiro 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone.
I hæmodynamiske studier har amlodipin ikke været forbundet med negativ inotropisk effekt, når det blev givet til mennesker eller levende dyr i det terapeutiske dosisinterval.
In haemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and humans, even when co-administered with beta blockers to humans.
Hypromellose, substitutionstype 2910 (3 mPa.s) Titandioxid (E171)
Hypromellose, substitution type 2910 (3 mPa.s) Titanium dioxide (E171) Iron oxide, yellow (E172) Macrogol 4000
DafiroDet er ikke nødvendigt at justere dosis hos patienter med let til moderat nedsat nyrefunktion.
No dosage adjustment is required for patients with mild to moderate renal impairment.
Sådan skal du tage Dafiro
How to take Dafiro
Dafiro 5 mg/80 mg filmovertrukne tabletter Dafiro 5 mg/160 mg filmovertrukne tabletter Dafiro 10 mg/160 mg filmovertrukne tabletter
Dafiro 5 mg/80 mg film-coated tablets Dafiro 5 mg/160 mg film-coated tablets Dafiro 10 mg/160 mg film-coated tablets
Meget sjælden (kan forekomme hos op til 1 ud af 10.000 personer): Nedsat antal hvide blodlegemer, nedsat antal blodplader, som kan medføre blå mærker og tendens til blødning; forhøjet blodsukker; hævede gummer, mavekatar; påvirket leverfunktion, leverbetændelse, gul hud, forhøjede leverenzymer (ses ved blodprøver); øget muskelspænding; årebetændelse, oftest med hududslæt; øget lysfølsomhed; en tilstand med stivhed, rysten og/eller bevægelsesforstyrrelser.
Very rare (may affect up to 1 in 10,000 people): Decreased number of white blood cells, decrease in blood platelets which may result in unusual brusing or easy bleeding (red blood cell damage); excess sugar in blood (hyperglycaemia); swelling of the gums, abdominal bloating (gastritis); abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests; increased muscle tension; inflammation of blood vessels often with skin rash, sensitivity to light; disorders combining rigidity, tremor and/or movement disorders.
Dafiro kan tages uden hensyn til fødeindtagelse.
Dafiro can be used with or without food.
Bulløs dermatit
Dermatitis bullous
Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer): Svimmelhed; kvalme og mavesmerter; mundtørhed; sløvhed; prikken og følelsesløshed i hænder eller fødder; svimmelhed; hurtigt hjerteslag inklusive hjertebanken; svimmelhed ved skift til stående stilling; hoste; diarré; forstoppelse; hududslæt; rødme af huden; hævelse af led, rygsmerter; ledsmerter.
Uncommon (may affect up to 1 in 100 people): Dizziness; nausea and abdominal pain; dry mouth; drowsiness, tingling or numbness of the hands or feet; vertigo; fast heart beat including palpitations; dizziness on standing up; cough; diarrhoea; constipation; skin rash, redness of the skin; joint swelling, back pain; pain in joints.
Ændring i afføringsvaner
Change of bowel habit
Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer): Humørsvingninger, angst, depression, søvnløshed, rysten, smagsforstyrrelser, besvimelse, manglende smertefølelse; synsforstyrrelser, nedsat syn, tinnitus; lavt blodtryk; nysen/snue pga. en betændelseslignende reaktion i næseslimhinden; fordøjelsesbesvær, opkastning; hårtab, øget svedtendens, hudkløe, misfarvninger af huden; vandladningsforstyrrelser, hyppigere vandladning, også om natten; erektionsproblemer, udvikling af bryster hos mænd, smerter, utilpashed, muskelsmerter, muskelkramper; vægtændring.
Uncommon (may affect up to 1 in 100 people): Mood changes, anxiety, depression, sleeplessness, trembling, taste abnormalities, fainting, loss of pain sensation; visual disturbances, visual impairment, ringing in the ears; low blood pressure; sneezing/runny nose caused by inflammation of the lining of the nose (rhinitis); indigestion, vomiting (being sick); hair loss, increased sweating, itchy skin, skin discolouration; disorder in passing urine, increased need to urinate at night, increased number of times of passing urine; inability to obtain an erection, discomfort or enlargement of the breasts in men, pain, feeling unwell, muscle pain, muscle cramps; weight increase or decrease.
Mørkegul, oval filmovertrukket tablet, præget med ”NVR” på den ene side og ”ECE” på den anden side.
Dark yellow, oval film-coated tablet, imprinted with “NVR” on one side and “ECE” on the other side.
Almindelig Almindelig Ikke almindelig
Uncommon Very rare Uncommon
Lysegul, oval filmovertrukket tablet, præget med ”NVR” på den ene side og ”UIC” på den anden side.
Light yellow, oval film-coated tablet, imprinted with “NVR” on one side and “UIC” on the other side.
Det skal du vide, før du begynder at tage Dafiro Sådan skal du tage Dafiro Bivirkninger
What Dafiro is and what it is used for What you need to know before you take Dafiro How to take Dafiro
Dafiro 5 mg/80 mg filmovertrukne tabletter
Dafiro 5 mg/80 mg film-coated tablets
Mørkegul, rund filmovertrukket tablet med facetslebne kanter, præget med ”NVR” på den ene side og ”NV” på den anden side.
Dark yellow, round film-coated tablet with bevelled edges, imprinted with “NVR” on one side and “NV” on the other side.
Valsartan Ikke kendt
Uncommon Not known
Synsforstyrrelser
Visual disturbance
primidon); - perikon; - glyceryltrinitrat (nitroglycerin) og andre nitrater eller andre stoffer, som kaldes ”vasodilatorer”; - medicin mod hiv/aids (f.eks. ritonavir, indinavir, nelfinavir); - medicin til behandling af svampeinfektioner (f.eks. ketoconazol, itraconazol); - medicin til behandling af bakterieinfektioner (f.eks. rifampicin, erythromycin, clarithromycin,
Your doctor may also check your kidney function; anticonvulsant agents (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone); St. John's wort; nitroglycerin and other nitrates, or other substances called “vasodilators”; medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir); medicines used to treat fungal infections (e.g. ketoconazole, itraconazole); medicines used to treat bacterial infections (such as rifampicin, erythromycin, clarithromycin, talithromycin); verapamil, diltiazem (heart medicines); simvastatin (a medicine used to control high cholesterol levels); dantrolene (infusion for severe body temperature abnormalities); medicines used to protect against transplant rejection (ciclosporin).
EU/1/06/371/034 280 filmovertrukne tabletter (4x70) EU/1/06/371/037 280 filmovertrukne tabletter (20x14)
EU/1/06/371/034 280 film-coated tablets (4x70) EU/1/06/371/037 280 film-coated tablets (20x14)
Dafiro 10 mg/160 mg filmovertrukne tabletter
Dafiro 10 mg/160 mg film-coated tablets
Nedsat leverfunktion
Weight decrease
Dafiro 5 mg/80 mg filmovertrukne tabletter Dafiro 5 mg/160 mg filmovertrukne tabletter Dafiro 10 mg/160 mg filmovertrukne tabletter amlodipin/valsartan
Dafiro 5 mg/80 mg film-coated tablets Dafiro 5 mg/160 mg film-coated tablets Dafiro 10 mg/160 mg film-coated tablets amlodipine/valsartan
EU/1/06/371/035 280 filmovertrukne tabletter (4x70) EU/1/06/371/038 280 filmovertrukne tabletter (20x14)
EU/1/06/371/035 280 film-coated tablets (4x70) EU/1/06/371/038 280 film-coated tablets (20x14)
Lysfølsomhed
Photosensitivity reaction
EU/1/06/371/036 280 filmovertrukne tabletter (4x70) EU/1/06/371/039 280 filmovertrukne tabletter (20x14)
EU/1/06/371/036 280 film-coated tablets (4x70) EU/1/06/371/039 280 film-coated tablets (20x14)
Er du i tvivl, så spørg lægen.
- If you have any further questions, ask your doctor or pharmacist.
Dafiro 10 mg/160 mg filmovertrukne tabletter amlodipin/valsartan
Dafiro 10 mg/160 mg film-coated tablets amlodipine/valsartan
Et multicenter, randomiseret, dobbeltblindet, aktivt kontrolleret, parallelgruppestudie undersøgte patienter, der ikke var tilstrækkeligt kontrolleret med amlodipin 10 mg, med henblik på en normalisering af blodtrykket (defineret som middel siddende diastolisk blodtryk <90 mmHg ved slutningen af studiet).
A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure <90 mmHg at the end of the trial) in patients not adequately controlled on amlodipine 10 mg in 78% of patients treated with amlodipine/valsartan 10 mg/160 mg, compared to 67% of patients remaining on amlodipine 10 mg.
Det anbefales at udføre ultralydsscanning for at tjekke nyrefunktionen og kraniet, hvis fosteret har været udsat for AIIA fra andet trimester.
Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.
Hver tablet indeholder 5 mg amlodipin og 80 mg valsartan.
Each tablet contains 5 mg amlodipine and 80 mg valsartan.
Aktivt kontrollerede studier med patienter, som ikke responderer på monoterapi Et multicenter, randomiseret, dobbeltblindet, aktivt kontrolleret, parallelgruppestudie undersøgte patienter, der ikke var tilstrækkeligt kontrolleret med valsartan 160 mg, med henblik på en normalisering af blodtrykket (defineret som middel siddende diastolisk blodtryk <90 mmHg ved slutningen af studiet).
Active-controlled trials in patients who were non-responders to monotherapy A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure <90 mmHg at the end of the trial) in patients not adequately controlled on valsartan 160 mg in 75% of patients treated with amlodipine/valsartan 10 mg/160 mg and 62% of patients treated with amlodipine/valsartan 5 mg/160 mg, compared to 53% of patients remaining on valsartan 160 mg.
Almindelig (kan forekomme hos op til 1 ud af 10 personer): Svimmelhed, døsighed; hjertebanken; ansigtsrødme, hævede ankler (ødemer); mavesmerter, kvalme.
Common (may affect up to 1 in 10 people): Dizziness, sleepiness; palpitations (awareness of your heart beat); flushing, ankle swelling (oedema); abdominal pain, feeling sick (nausea).
Dafiro 5 mg/160 mg filmovertrukne tabletter
Dafiro 5 mg/160 mg film-coated tablets
Dafiro 5 mg/80 mg tabletter er runde og mørkegule, præget med ”NVR” på den ene side og ”NV” på den anden side.
What Dafiro looks like and contents of the pack Dafiro 5 mg/80 mg tablets are round and dark yellow with “NVR” on one side and “NV” on the other side.
(en tilstand, hvor hjertet ikke er i stand til at opretholde tilstrækkelig blodforsyning til kroppen).
if you have narrowing of the aortic valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).
Koordinationsbesvær
Coordination abnormal
I stedet foretrækkes alternative behandlinger med bedre dokumenterede sikkerhedsprofiler ved amning, især ved amning af et nyfødt spædbarn eller et for tidligt født spædbarn.
No information is available regarding the use of Dafiro during breast-feeding, therefore Dafiro is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Dafiro 5 mg/80 mg filmovertrukne tabletter amlodipin/valsartan
Dafiro 5 mg/80 mg film-coated tablets amlodipine/valsartan
Smerte
Headache
Nyresvigt og nedsat nyrefunktion
Renal failure and impairment
Hver tablet indeholder 5 mg amlodipin og 160 mg valsartan.
Each tablet contains 5 mg amlodipine and 160 mg valsartan.
Dafiro 5 mg/160 mg filmovertrukne tabletter amlodipin/valsartan
Dafiro 5 mg/160 mg film-coated tablets amlodipine/valsartan
Faryngolaryngeale smerter
Pharyngolaryngeal pain Uncommon Rhinitis
Forhøjet kalium i blodet
Blood potassium increased
EU/1/06/371/001 7 filmovertrukne tabletter EU/1/06/371/002 14 filmovertrukne tabletter EU/1/06/371/003 28 filmovertrukne tabletter EU/1/06/371/004 30 filmovertrukne tabletter EU/1/06/371/005 56 filmovertrukne tabletter EU/1/06/371/006 90 filmovertrukne tabletter EU/1/06/371/007 98 filmovertrukne tabletter EU/1/06/371/008 280 filmovertrukne tabletter EU/1/06/371/025 56x1 filmovertrukket tablet (enhedsdosis) EU/1/06/371/026 98x1 filmovertrukket tablet (enhedsdosis) EU/1/06/371/027 280x1 filmovertrukket tablet (enhedsdosis)
EU/1/06/371/001 7 film-coated tablets EU/1/06/371/002 14 film-coated tablets EU/1/06/371/003 28 film-coated tablets EU/1/06/371/004 30 film-coated tablets EU/1/06/371/005 56 film-coated tablets EU/1/06/371/006 90 film-coated tablets EU/1/06/371/007 98 film-coated tablets EU/1/06/371/008 280 film-coated tablets EU/1/06/371/025 56x1 film-coated tablet (unit dose) EU/1/06/371/026 98x1 film-coated tablet (unit dose) EU/1/06/371/027 280x1 film-coated tablet (unit dose)
Hver tablet indeholder 10 mg amlodipin og 160 mg valsartan..
Each tablet contains 10 mg amlodipine and 160 mg valsartan.
EU/1/06/371/017 7 filmovertrukne tabletter EU/1/06/371/018 14 filmovertrukne tabletter EU/1/06/371/019 28 filmovertrukne tabletter EU/1/06/371/020 30 filmovertrukne tabletter EU/1/06/371/021 56 filmovertrukne tabletter EU/1/06/371/022 90 filmovertrukne tabletter EU/1/06/371/023 98 filmovertrukne tabletter EU/1/06/371/024 280 filmovertrukne tabletter EU/1/06/371/031 56x1 filmovertrukket tablet (enhedsdosis) EU/1/06/371/032 98x1 filmovertrukket tablet (enhedsdosis) EU/1/06/371/033 280x1 filmovertrukket tablet (enhedsdosis)
EU/1/06/371/017 7 film-coated tablets EU/1/06/371/018 14 film-coated tablets EU/1/06/371/019 28 film-coated tablets EU/1/06/371/020 30 film-coated tablets EU/1/06/371/021 56 film-coated tablets EU/1/06/371/022 90 film-coated tablets EU/1/06/371/023 98 film-coated tablets EU/1/06/371/024 280 film-coated tablets EU/1/06/371/031 56x1 film-coated tablet (unit dose) EU/1/06/371/032 98x1 film-coated tablet (unit dose) EU/1/06/371/033 280x1 film-coated tablet (unit dose)
Almindelig Ikke almindelig
Common Uncommon